VBI Vaccines (VBIV) Receives a New Rating from Oppenheimer


VBI Vaccines (VBIV) received a Buy rating and a $9 price target from Oppenheimer analyst Leland Gershell today. The company’s shares closed yesterday at $1.77.

Gershell noted:

“We are initiating coverage on VBIV with an Outperform rating and a 12- to 18- month price target of $9. An innovator in the vaccine field, VBIV is advancing three candidates through clinical development for infection prevention (hepatitis B, CMV) and cancer treatment (glioblastoma). We see pivotal-stage hepB vaccine Sci-B-Vac as low risk, and its ability to protect less tractable populations should make it a niche competitor. The company’s eVLP technology is being leveraged for CMV (to enter Phase 2 in late 2019) as well as glioblastoma (in Phase 1/2). With a ~$160M EV and ample cash post a recent raise, we believe positive newsflow from any of VBIV’s programs could spark share appreciation.”

According to TipRanks.com, Gershell is a 1-star analyst with an average return of -4.7% and a 38.7% success rate. Gershell covers the Healthcare sector, focusing on stocks such as Avenue Therapeutics Inc, Evofem Biosciences Inc, and AzurRx BioPharma Inc.

Currently, the analyst consensus on VBI Vaccines is a Moderate Buy with an average price target of $9.50.

See today’s analyst top recommended stocks >>

Based on VBI Vaccines’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $15.37 million. In comparison, last year the company had a GAAP net loss of $11.54 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

VBI Vaccines, Inc. is a biopharmaceutical company, which develops vaccines for infectious disease and immuno-oncology. Its pipeline includes Sci-B-Vac, CMV Vaccine, GBM Immunotherapy, MB Immunotherapy, and Zika Vaccine. The company was founded on July 9, 2015 is headquartered in Cambridge, MA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts